Veloxis Begins Phase 2 Trial of Pegrizeprument
Research Triangle Park, North Carolina, August 31, 2026 Veloxis Pharmaceuticals, Inc. announced that the first patient has been dosed...
Clinical Trials for New Therapy
PMV Pharma Reports 46% ORR in Ovarian Cancer Trial
PRINCETON, N.J., August 31, 2026 PMV Pharmaceuticals announced updated interim data from the Phase 2 pivotal portion of the...
Arch Biopartners Gains U.S. IRB Approval for LSALT Phase II
TORONTO, Canada, August 31, 2026 Arch Biopartners Inc. announced that it has received central Institutional Review Board (IRB) approval...
Amgen Shows Repatha Reduces Death Risk in High-Risk Patients
Thousand Oaks, Calif. – August 31, 2026 Amgen announced new Phase 3 findings showing that Repatha® (evolocumab) reduced the...
BeOne Reports New Phase 3 Survival Data for ZIIHERA
San Carlos, Calif. – August 31, 2026 BeOne Medicines announced new Phase 3 overall survival data from the HERIZON-GEA-01...
Tenax Therapeutics Reports LEVEL Data at ESC Congress 2026
Tenax Therapeutics, Chapel Hill, North Carolina, August 29, 2026 Tenax Therapeutics announced the presentation of additional Phase 3 LEVEL...
Cytokinetics Highlights Phase 3 Aficamten Data at ESC
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 Cytokinetics, Incorporated announced additional clinical data for aficamten from the ACACIA-HCM and...
Alnylam Presents ATTR-CM Data at ESC Congress 2026
Cambridge, Mass. – August 30, 2026 Alnylam Pharmaceuticals announced new clinical data at the European Society of Cardiology (ESC)...
Arrowhead Reports Phase 3 Plozasiran Data Reducing Pancreatitis
Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...
HUTCHMED Reports Phase III SANOVO PFS Benefit in EGFR NSCLC
Hong Kong, Shanghai & Florham Park, NJ – August 31, 2026 HUTCHMED (China) Limited announced positive high-level results from...